Mercury Laboratories Ltd

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators amid mixed financial and valuation metrics. While the company’s recent quarterly performance shows promising growth, long-term fundamentals remain weak, prompting a cautious stance from analysts.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 26 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Mercury Laboratories Ltd has declined to a fresh 52-week low of Rs.770, marking a significant downturn in its stock performance amid broader market weakness and sectoral underperformance. The stock’s fall reflects a combination of subdued long-term growth metrics and recent trading volatility.

Mercury Laboratories Ltd has touched a new 52-week low of Rs.775 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance trends. The stock underperformed its sector and continues to trade below all major moving averages, reflecting ongoing challenges in maintaining upward momentum.

Mercury Laboratories Ltd has touched a new 52-week low of Rs.775 today, marking a significant decline in its stock price amid broader sector underperformance and subdued long-term growth metrics.

Mercury Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 26 Feb 2026. This revision reflects deteriorating technical indicators, subdued financial trends, and persistent valuation concerns despite some recent positive quarterly results. The downgrade highlights growing investor caution amid the company’s ongoing underperformance relative to benchmarks and peers.

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, driven primarily by improvements in technical indicators despite ongoing challenges in long-term fundamentals and valuation metrics. This nuanced shift reflects a cautious optimism amid mixed signals across quality, valuation, financial trends, and technical analysis.

Mercury Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 12 Feb 2026. This revision reflects deteriorating quality metrics, bearish technical indicators, and a subdued financial trend, despite some positive quarterly results. The company’s Mojo Score now stands at 29.0, underscoring significant concerns for investors.

Mercury Laboratories Ltd., the Mumbai-based pharmaceutical manufacturer, reported a striking 185.29% year-on-year surge in net profit to ₹0.97 crores for Q1 FY26 (Apr-Jun'25), yet the headline numbers conceal mounting operational pressures that have left investors questioning the sustainability of this micro-cap company's performance. Trading at ₹805.15 with a market capitalisation of ₹97.00 crores, the stock has declined 12.61% sequentially from Q4 FY25's ₹1.11 crores profit and underperformed its sector by 11.86 percentage points over the past year, signalling deeper concerns beneath the surface-level profit growth.

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 26 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 January 2026, providing investors with the latest insights into its performance and outlook.

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Mercury Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s evaluation metrics, providing investors with a comprehensive understanding of its current standing.